CytoReason and Summit Pharmaceuticals International Announce the Introduction of anAI Platform to One of Japan’s Top Pharmaceutical Companies
The first implementation will leverage CytoReason’s technology to progress the development ofa clinical asset, using CytoReason’s disease model.

Tokyo - Japan, Tel Aviv, Israel -- September 30, 2021 -- CytoReason, an AI company
developing computational disease models for discovery and clinical drug development, andSummit Pharmaceuticals International (SPI), a Japanese company providing service andproducts to the pharmaceutical industry (wholly-owned subsidiary of Sumitomo Corporation),
today announced that CytoReason has entered the Japanese market, with its technology being
utilized by one of Japan’s top pharmaceutical companies.
CytoReason’s AI platform will use its disease model, along with clinical data from the Japanesepharmaceutical company, to help it gain a better understanding of how its drug behaves on amolecular level, relative to similar drugs on the market.
This is the first-ever announced collaboration between an Israeli company and a Japanesepharmaceutical company to bring AI to clinical drug development. The collaboration will explore
the relationship between disease mechanisms and drug MoA in order to increase the drug’svaluation in immunology. It is especially impactful as Japan has the third largest pharmaceuticalmarket in the world.
CytoReason helps pharma and biotech companies accelerate drug discovery and developmentwith the use of its cell-centered computational models and proprietary data. The company’stechnology enables scientists to gather critical information on the body’s immune functioning,which ultimately speeds up the scientific process and brings life-saving drugs to market faster andat a reduced cost. R&D using AI technology is becoming essential in the pharmaceutical field andthe industry has taken keen interest in CytoReason’s technology. Sumitomo Corporation groupfacilitates digital transformation in various industries, and SPI intends to further support datadriven drug discovery and clinical development by CytoReason’s proprietary AI/machine learning
platform.
“We’re thrilled to enter the Japanese market with such an important player in the country’s
pharmaceutical industry,” said David Harel, CEO and Co-founder of CytoReason. “Thiscollaboration represents a meaningful step forward for our company and for the global
pharmaceutical industry.”“We are very delighted that CytoReason initiated a project in Japanese market.” said Katsuya
Okuyama, President & CEO of SPI. “We will continue to contribute to the healthcare industry
through collaboration with CytoReason.”###About CytoReason
CytoReason's computational model of the human body simulates human disease on a cellularlevel, minimizes the need for animal trials, and makes human trials more focused and accurate.
With CytoReason's proprietary database and AI-led platform, pharma and biotech companies
make data-driven decisions in a fraction of the time and cost. To date, six of the world's top ten
pharma companies use CytoReason's technology to bring the right drug, to the right patient, atthe right price. For more information, visit www.cytoreason.com.
About SPISPI is a provider of high-quality integrated products and services to the pharmaceutical industry,from research equipment and bioresources for drug discovery, pharmaceutical licensing andresearch alliance support, to manufacturing of APIs, intermediates for pharmaceuticals, genericdrugs and biologics. SPI plays a central role in the medical science business line as a groupcompany of Sumitomo Corporation, with one of the leading global trading companies, 113
locations in 66 countries, and 22 locations in Japan, with a diverse range of products and services.
For more information, visit www.summitpharma.co.jp.
Media Contact
Yael Hart
GK for CytoReason
yael@gkpr.com+972 53-335-9896